American Heart Journal
Volume 156, Issue 2 , Pages 234-240 , August 2008

Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting

Received 11 January 2008 ,Accepted 13 March 2008.

References 

  1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: executive summary. Circulation. 2007;116:803–877
  2. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non–ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  3. Apple FS, Wu AHB, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810–824
  4. Wang TJ, Mort EA, Nordberg P, et al. A utilization management intervention to reduce unnecessary testing in the coronary care unit. Arch Intern Med. 2002;162:1885–1890
  5. Turner SJ, Ketch TR, Gandhi SK, et al. Routine hematological clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J. 2008;doi:10.1016/j.ahj.2007.11.037 (Electronic publication 2008 Jan 21)
  6. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–1809
  7. Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acute phase reactants and prognosis after percutaneous coronary intervention. Cardiovascular Res. 2003;60:136–140
  8. Becker RC, Cannon CP, Bovill EG, et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non–Q wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol. 1996;78:142–147
  9. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96:4204–4210
  10. Mackie IJ, Kitchen S, Machin SJ, et al. Guidelines on fibrinogen assays. Br J Haematol. 2003;121:396–404
  11. Rossi E, Mondonica P, Lombardi A, et al. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Throm Res. 1988;52:452–468
  12. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristics curves: a non-parametric approach. Biometrics. 1988;44:837–845
  13. Greenland P. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med. 2005;165:2454–2456
  14. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894–1904
  15. Gralnick HR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood. 1984;64:797–800
  16. Kerr R, Stirling D, Ludlam C. Interleukin 6 and haemostasis. Br J Haematol. 2001;115:3–12
  17. Woodward M, Rumley A, Welsh P, et al. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost. 2007;5:1795–1800
  18. Flick MJ, LaJeunesse CM, Talmage KE, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin aMb2 binding motif. J Clin Invest. 2007;117:3224–3235
  19. Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J. 2007;28:1409–1417
  20. Bode C, Zirlik A. STEMI and NSTEMI: the dangerous brothers. Eur Heart J. 2007;28:1403–1404
  21. De Cristofaro R, Landolfi R. Measurement of plasma fibrinogen concentration by prothrombin-time–derived method : applicability and limitations. Blood Coagul Fibrinolysis. 1998;9:251–259
  22. Lowe GDO, Woodward M, Rumley A, et al. Associations of plasma fibrinogen assays, C-reactive protein and interleukin-6 with previous myocardial infarction. J Thromb Haemost. 2003;1:2312–2316
  23. Wiviott S, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta. 2004;346:119–128
  24. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335–339

PII: S0002-8703(08)00221-4

doi: 10.1016/j.ahj.2008.03.015

American Heart Journal
Volume 156, Issue 2 , Pages 234-240 , August 2008

Article Tools

* Image Usage & Resolution